GB0905664D0 - Compounds for treatment of duchenne muscular dystrophy - Google Patents

Compounds for treatment of duchenne muscular dystrophy

Info

Publication number
GB0905664D0
GB0905664D0 GBGB0905664.9A GB0905664A GB0905664D0 GB 0905664 D0 GB0905664 D0 GB 0905664D0 GB 0905664 A GB0905664 A GB 0905664A GB 0905664 D0 GB0905664 D0 GB 0905664D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treatment
muscular dystrophy
duchenne muscular
duchenne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0905664.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GBGB0905664.9A priority Critical patent/GB0905664D0/en
Publication of GB0905664D0 publication Critical patent/GB0905664D0/en
Priority to PCT/EP2009/065132 priority patent/WO2010112093A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0905664.9A 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy Ceased GB0905664D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0905664.9A GB0905664D0 (en) 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy
PCT/EP2009/065132 WO2010112093A1 (en) 2009-04-02 2009-11-13 Benzoxazoles for the treatment of duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905664.9A GB0905664D0 (en) 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0905664D0 true GB0905664D0 (en) 2009-05-13

Family

ID=40672145

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0905664.9A Ceased GB0905664D0 (en) 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy

Country Status (2)

Country Link
GB (1) GB0905664D0 (en)
WO (1) WO2010112093A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9246108B2 (en) 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
PL3186233T3 (en) * 2014-08-29 2022-02-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein
ES2818107T3 (en) 2014-08-29 2021-04-09 Chdi Foundation Inc Huntingtin Protein Imaging Probes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
NZ570625A (en) * 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
WO2010112093A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of duchenne muscular dystrophy
PL2170396T3 (en) Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
GB0915515D0 (en) Treatment of vasculoproliferative conditions
PL2490694T3 (en) Rostafuroxine for pharmacogenomic treatment of cardiovascular conditions
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
ZA200806986B (en) Treatment of duchenne muscular dystrophy
IL201908A0 (en) Polymorphs of a compound for the treatment of duchenne muscular dystrophy
PL2576582T3 (en) Treatment of muscular dystrophy
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0809314D0 (en) Compounds for treating muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
PT2536398T (en) Treatment of osteoporosis
GB0901417D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0902411D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0901794D0 (en) Compounds for treating muscular dystrophy
GB0803906D0 (en) Compounds for treating duchenne muscular dystrophy
GB0807216D0 (en) Drug combination for the treatment of duchenne muscular dystrophy
GB0913427D0 (en) Compounds for treatment of imflammation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)